Asia-Pacific Multifocal IOLs Market Segmentation, By Type (Soft Lens and Rigid Gas Permeable (RGP, or Hard) Lens), Design (Simultaneous Vision Lenses and Segmented Multifocal Lenses), Packaging (Pack of 6, Pack of 30, and Others), Product Type (Diffractive Multifocal IOLs, Hybrid Multifocal IOLs and Refractive Multifocal IOLs), Brand (Technis Symphony, Zeiss Trifocal, and Others), Incision Size (1.8 MM, 2.2 MM, and Others), Pupil Dependence (Dependent and Independent), Power (Low Power and High Power), Material (Hydrophobic Acrylic, Silicon & Collamer, Lehfilcon-A, Somofilcon A and Others), Adjustability (Light Reduction and Non Reduction), Price Range (Premium Lens and Standard Lens), Flexibility (Foldable IOLs and Rigid IOLs), Age Group (Above 51 Years, 41-50 Years and Below 40 Years), Gender (Female and Male), Application (Vision Disorder, Cataract, Corneal Disorder, and Others), End User (Hospitals, Ophthalmology Clinics, Eye Research Institutes, Ambulatory Surgery Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others) - Industry Trends and Forecast to 2031.
Asia-Pacific Multifocal IOLs Market Analysis and Insights
Increasing prevalence of cataracts is expected to drive rising prevalence of heat-related illnesses in the Asia-Pacific multifocal IOLs market.
Data Bridge Market Research analyzes that the Asia-Pacific multifocal IOLs market is expected to reach USD 370.44 million by 2031 from USD 241.66 million in 2023, growing with a CAGR of 6.0% in the forecast period of 2024 to 2031.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016–2021)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Type (Soft Lens and Rigid Gas Permeable (RGP, or Hard) Lens), Design (Simultaneous Vision Lenses and Segmented Multifocal Lenses), Packaging (Pack of 6, Pack of 30, and Others), Product Type (Diffractive Multifocal IOLs, Hybrid Multifocal IOLs and Refractive Multifocal IOLs), Brand (Technis Symphony, Zeiss Trifocal, and Others), Incision Size (1.8 MM, 2.2 MM, and Others), Pupil Dependence (Dependent and Independent), Power (Low Power and High Power), Material (Hydrophobic Acrylic, Silicon & Collamer, Lehfilcon-A, Somofilcon A and Others), Adjustability (Light Reduction and Non Reduction), Price Range (Premium Lens and Standard Lens), Flexibility (Foldable IOLs and Rigid IOLs), Age Group (Above 51 Years, 41-50 Years and Below 40 Years), Gender (Female and Male), Application (Vision Disorder, Cataract, Corneal Disorder, and Others), End User (Hospitals, Ophthalmology Clinics, Eye Research Institutes, Ambulatory Surgery Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others)
|
|
Countries Covered
|
China, India, Australia, South Korea, Japan, Indonesia, Malaysia, Singapore, Thailand, Philippines, Vietnam, and Rest of Asia-Pacific
|
|
Market Players Covered
|
Johnson & Johnson, Inc., Hoya Medical Singapore Pte. Ltd. or Its Affiliates, Zeiss Group, Alcon Inc., Rayner Group, Lenstec, Inc., Aurolab, Excellent Hi-Care Pvt Ltd, Sav-Iol SA, Vsy Biotechnology Gmbh, Hanita Lenses Ltd, Care Group, Iolart, Omni Lens Pvt. Ltd., Ophtec BV and, among others.
|
Market Definition
The Asia-Pacific multifocal (IOLs) market refers to the segment of the ophthalmic industry that focuses on the development, production, and distribution of advanced intraocular lenses designed to correct presbyopia and other vision impairments in patients undergoing cataract surgery or lens replacement procedures. Multifocal IOLs are engineered to provide clear vision at multiple distances—near, intermediate, and far—reducing or eliminating the need for glasses or contact lenses after surgery. This market is driven by an aging Asia-Pacific population, increasing prevalence of cataracts, advancements in lens technology, rising awareness of premium IOL options, and growing demand for improved quality of life among patients seeking better visual outcomes post-surgery.
Asia-Pacific Multifocal (IOLs) Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Driver
- Increasing Prevalence of Cataracts
The increasing prevalence of cataracts, particularly among the aging population, serves as a significant driver for the Asia-Pacific multifocal intraocular lenses (IOLs) market. As cataracts remain the leading cause of blindness and visual impairment worldwide, the demand for effective and long-lasting solutions has surged. Multifocal IOLs offer a compelling alternative to traditional lenses by enabling patients to focus at multiple distances without the need for additional corrective eyewear. This capability is particularly appealing to a growing demographic of older adults who wish to maintain an active lifestyle post-cataract surgery. With the Asia-Pacific population aging and the incidence of cataracts rising in tandem, healthcare providers and patients alike are increasingly turning to advanced multifocal IOLs to restore clear vision across different focal points. Furthermore, technological advancements in lens design, such as improved light distribution and reduced halos and glare, have enhanced patient outcomes, driving greater adoption. The convergence of these factors, coupled with an increasing awareness of the benefits of multifocal IOLs, is propelling market growth as more individuals opt for these innovative lenses to improve their quality of life following cataract surgery.
Restraint
- Strict Regulatory Requirements for Developing, Approving, and Commercializing IOLS
Stringent regulatory challenges present a significant and multifaceted restraint in the Asia-Pacific multifocal intraocular lenses (IOLs) market, as the pathway to developing, obtaining approval, and commercializing these advanced medical devices is fraught with complex, time-consuming, and costly hurdles that vary significantly across different regions. Regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and their counterparts in other parts of the world impose stringent requirements for the clinical evaluation of multifocal IOLs, necessitating robust and comprehensive safety and efficacy data to ensure that these devices meet the highest standards of patient care. This process often involves multiple phases of clinical trials, extensive pre-market approval submissions, and rigorous post-market surveillance, each step of which demands significant financial investment, human resources, and time. Companies are required to meticulously document every aspect of their product development, from the initial design and manufacturing processes to the long-term performance of the IOLs in diverse patient populations. This extensive documentation must not only prove the device's safety and effectiveness but also demonstrate compliance with the ever-evolving regulatory guidelines, which can differ significantly between regions, further complicating the approval process. The variability in regulatory standards and the necessity to obtain approval in multiple jurisdictions can lead to protracted delays in bringing new multifocal IOLs to market, as companies must often tailor their submissions to meet the specific requirements of each regulatory authority.
Opportunity
- Increasing Adoption of Multifocal Premium IOLS
The adoption of premium multifocal intraocular lenses (IOLs) is steadily increasing as patients and healthcare providers recognize their advanced capabilities in restoring vision across multiple distances. These lenses offer significant improvement over standard IOLs by reducing or even eliminating the need for glasses after cataract surgery, enhancing patients' quality of life. As awareness grows about the benefits of premium multifocal IOLs—such as clearer vision at near, intermediate, and far distances, more patients are opting for these advanced lenses, particularly those who prioritize maintaining an active lifestyle without the burden of corrective eyewear. This trend is supported by technological advancements that continues to refine the visual outcomes of these lenses, making them a more attractive choice for both patients and surgeons
Challenge
- Rising Competition from Other Technologies
The multifocal intraocular lens (IOL) market faces significant challenges in the coming years, primarily due to the rise of alternative vision correction technologies that are increasingly gaining attraction. Technologies such as extended depth-of-focus (EDOF) IOLs, accommodative IOLs, and trifocal IOLs are presenting viable alternatives to traditional multifocal lenses, each offering distinct advantages that caters to specific patient needs. EDOF IOLs, for instance, provides a continuous range of vision with fewer visual disturbances like halos and glare, which are common concerns with multifocal IOLs. Accommodative IOLs mimic the eye's natural focusing ability, offering a more seamless visual experience without the need for multiple focal points. Trifocal IOLs, on the other hand, offers a broader range of clear vision across all distances, further reducing the need for multifocal lenses.
Recent Developments
- In June 2024, the ZEISS Group actively promotes eye health during Cataract Awareness Month by conducting educational campaigns and free eye screenings. Their initiatives aim to raise awareness about cataract prevention and treatment, emphasizing the importance of early detection and modern surgical solutions. ZEISS's efforts include partnerships with local healthcare providers to improve access to quality eye care and support communities in managing and preventing vision impairment
- In December 2024, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc., a Asia-Pacific biotechnology company known for discovering, developing, and commercializing transformative cancer medicines. Pfizer acquired all outstanding common stock of Seagen for USD 229 per share in cash, totalling In March 2023, The ZEISS Group design and innovate IOL and OVD Portfolio to address both patient needs and surgeon preferences. Combining innovation and precision, it offers a comprehensive selection of cataract consumables and implants, tailored for monofocal, toric, and refractive cataract surgeries
- In April 2024, Alcon, the Asia-Pacific leader in eye care dedicated to helping people see brilliantly, showcased approximately 100 company-supported and investigator-led data presentations demonstrating its latest innovative efforts aimed at optimizing patient outcomes at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 5-8 in Boston. In addition, the company hosts multiple peer-to-peer symposia and in-booth demonstrations of its industry-leading implantables and devices, including the Clareon intraocular lens (IOL) portfolio, cloud-based SMARTCataract surgical planner, Hydrus Microstent and more
Asia-Pacific Multifocal IOLs Market Scope
Asia-Pacific multifocal IOLs market is categorized into seventeen notable segments which are based on the type, design, packaging, product type, brand, incision size, pupil dependence, power, material, adjustability, price range, flexibility, age group, gender, application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Soft Lens
- Rigid Gas Permeable (RGP, or Hard) Lens
On the basis of type, the market is segmented into soft lens and Rigid Gas Permeable (RGP, or Hard) lens.
Design
- Simultaneous Vision Lenses
- Segmented Multifocal Lenses
On the basis of design, the market is segmented into simultaneous vision lenses and segmented multifocal lenses.
Packaging
- Pack of 6
- Pack of 30
- Others
On the basis of packaging, the market is segmented into pack of 6, pack of 30, and others.
Product Type
- Diffractive Multifocal IOLs
- Hybrid Multifocal IOLs
- Refractive Multifocal IOLs
On the basis of product type, the market is segmented into diffractive multifocal IOLs, hybrid multifocal IOLs, and refractive multifocal IOLs.
Brand
- Technis Symphony
- Zeiss Trifocal
- Others
On the basis of brand, the market is segmented into technis symphony, zeiss trifocal, and others.
Incision Size
- 1.8 MM
- 2.2 MM
- Others
On the basis of incision size, the market is segmented into 1.8 MM, 2.2 MM, and others.
Pupil Dependence
- Dependent
- Independent
On the basis of pupil dependence, the market is segmented into dependent and independent.
Power
- Low Power
- High Power
On the basis of power, the market is segmented into low power and high power.
Material
- Hydrophobic Acrylic
- Silicon & Collamer
- Lehfilcon-A
- Somofilcon A
- Others
On the basis of material, the market is segmented into hydrophobic acrylic, silicon & collamer, lehfilcon-A, somofilcon A, and others.
Adjustability
- Light Reduction
- Non Reduction
On the basis of adjustability, the market is segmented into light reduction and non reduction.
Price Range
- Premium Lens
- Standard Lens
On the basis of price range, the market is segmented into premium lens and standard lens.
Flexibility
- Foldable IOLs
- Rigid IOLs
On the basis of flexibility, the market is segmented into foldable IOLs and rigid IOLs.
Age Group
- Above 51 Years
- 41-50 Years
- Below 40 Years
On the basis of age group, the market is segmented into above 51 years, 41-50 years and, Below 40 years.
Gender
- Female
- Male
On the basis of gender, the market is segmented into female and male.
Application
- Vision Disorder
- Cataract
- Corneal Disorder
- Others
On the basis of application, the market is segmented into vision disorder, cataract, corneal disorder and others.
End User
- Hospitals
- ophthalmology Clinics
- Eye Research Institutes
- Ambulatory Surgery Centers
- Others
On the basis of end user, the market is segmented into hospitals, ophthalmology clinics, eye research institutes, ambulatory surgery centers, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the market is segmented into direct tender, retail sales and others.
Asia-Pacific Multifocal IOLs Market Regional Analysis/Insights
Asia-Pacific multifocal IOLs market is categorized into seventeen notable segments which are based on the type, design, packaging, product type, brand, incision size, pupil dependence, power, material, adjustability, price range, flexibility, age group, gender, application, end user, and distribution channel.
The country covered in this market report are China, India, Australia, South Korea, Japan, Indonesia, Malaysia, Singapore, Thailand, Philippines, Vietnam, and rest of Asia-Pacific.
China is expected to dominate and fastest growing country in Asia-Pacific region due to technological advancement & innovations in IOL design.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Multifocal IOLs Market Dynamics Market Share Analysis
Asia-Pacific multifocal IOLs market dynamics market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major market players operating in the market are Johnson & Johnson, Inc., Hoya Medical Singapore Pte. Ltd. or Its Affiliates, Zeiss Group, Alcon Inc., Rayner Group, Lenstec, Inc., Aurolab, Excellent Hi-Care Pvt Ltd, Sav-Iol SA, Vsy Biotechnology Gmbh, Hanita Lenses Ltd, Care Group, Iolart, Omni Lens Pvt. Ltd., Ophtec BV and, among others.
SKU-